Aethlon Medical Inc. (AEMD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 5, 2025, concerns Aethlon Medical, Inc., a Nevada corporation headquartered in San Diego, California. The filing addresses a corporate action regarding the Company's capital structure.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure adjustment rather than financial performance results.
Material Changes
The Board of Directors has approved a 1-for-8 reverse stock split of all issued and outstanding common stock. This action follows stockholder approval at a Special Meeting on May 13, 2025, which authorized a split ratio between 1-for-5 and 1-for-12. Key details include:
- Effective Time: 5:00 p.m. Eastern Time on June 6, 2025.
- Trading Resumption: June 9, 2025, on a split-adjusted basis on The Nasdaq Capital Market.
- Adjustments: Proportionate adjustments will be made to the exercise prices and share counts of outstanding stock options, restricted stock units, and warrants.
- Fractional Shares: No fractional shares will be issued; holders of fractional interests will receive one whole share.
- Ownership: The split will not affect any stockholder's percentage ownership, except where rounding results in an additional share.
- New CUSIP: 00808Y 505.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future operations, or specific risk factors beyond the standard implications of a reverse stock split. The primary purpose is to notify the market of the implementation of the previously authorized reverse split.
Investor Verification Checklist
- Confirm the 1-for-8 reverse stock split ratio and the June 6, 2025 effective time.
- Verify the new CUSIP number (00808Y 505) for trading purposes starting June 9, 2025.
- Check brokerage accounts for the treatment of fractional shares (rounded up to one whole share).
- Review adjustments to outstanding equity awards (options, RSUs, warrants) regarding share counts and exercise prices.